According to IDEXX Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 42.4324. At the end of 2022 the company had a P/E ratio of 50.2.
Year | P/E ratio | Change |
---|---|---|
2022 | 50.2 | -33.31% |
2021 | 75.3 | 2.64% |
2020 | 73.4 | 39.42% |
2019 | 52.6 | 22.55% |
2018 | 43.0 | -17.58% |
2017 | 52.1 | 10.24% |
2016 | 47.3 | 34.23% |
2015 | 35.2 | -14.47% |
2014 | 41.2 | 36.68% |
2013 | 30.1 | 5.21% |
2012 | 28.6 | 6.07% |
2011 | 27.0 | -4.81% |
2010 | 28.4 | 10.4% |
2009 | 25.7 | 38.17% |
2008 | 18.6 | -51.47% |
2007 | 38.3 | 44% |
2006 | 26.6 | -10.9% |
2005 | 29.9 | 25.29% |
2004 | 23.8 | -13.98% |
2003 | 27.7 | 13.04% |
2002 | 24.5 | -2.83% |
2001 | 25.2 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.